Small neuroscience biotechs that are looking to develop new technologies targeting addiction, anxiety, depression and PTSD, have seen their shares soar as high as 200% or more in recent months.

If you’re looking for the next big stock opportunity... comparable 5G boom of the last few years...  or missed the cannabis boom...
Then there is some very good news for you!

We may be on the cusp of a new mega-boom in neuro-pharmaceutical stocks comparable to the medical cannabis craze of a few years ago.  

Dozens of privately-held startups, many backed by Silicon Valley venture capitalists, are now researching the use of technology and digital assessment programs with new pharmaceutical treatments to address the growing epidemic of mental health disorders in (Globally) North America. More than 300 million people worldwide suffer from depression alone¹ and mental health related illness costing the global economy trillions of dollars.²

A handful of these publicly traded neuro-pharmaceutical stocks have seen eye-popping gains recently:

• Field Trip Health (FTRP.CN), which offers psychotherapy using the legal drug esketamine at its clinics in Toronto and Los Angeles, recently went public and saw its shares jump 124%³ between November and December;

• Compass Pathways (CMPS), the first Biotech researching new psychedelic treatments for mental illness to be listed on a U.S. exchange (the Nasdaq), saw its shares skyrocket to over $56⁴. An increase by as much as 233% above its initial offering price of $17 per share in just a few months;

 

• Mind Medicine (OTCQB:MMEDF; CSE:MMED), another publicly traded neuro-pharmaceutical company developing new therapies to treat mental health disorders, saw its shares soar 1,332%⁵ in fall 2020.

 
And these gains may be just the beginning.  

They reflect a resurgent interest in breakthrough mental health therapeutics by both private business and the U.S. government in the wake of the Covid-19 pandemic.

---

Psychoactive Compounds to Treat Depression, Anxiety and PTSD-Post-Traumatic Stress 

In addition to Mind Cure seeking to develop state-of-the-art digital therapeutics for mental health, Mind Cure (OTCQB: MCURF; CSE: MCUR) is also seeking to develop next-generation psychoactive and Pyschedelic compounds to treat a wide variety of mental health disorders. The compounds being studied include MDMA, esketamine, psilocybin, ibogaine and ayahuasca.

Like medical marijuana a few years ago, there are signs that the use of these compounds for mental health may be making a comeback – and could be a phenomenal opportunity for early investors. The Navy Seals Foundation contributed $50,000 to a PTSD research project using the psychedelic MDMA, that could someday help military veterans suffering from PTSD.⁶

This is a huge development because the last major neuroscience drug to treat depression, Prozac, was released 32 years ago.

Mind Cure (OTCQB: MCURF; CSE: MCUR) seeks to identify and commercialize the therapeutic potential of psychoactive and psychedelic compounds, such as psilocybin, as part of its future product candidates.

While targeted in the 1960s, these compounds show promise in a medical context as breakthrough treatments⁷ for debilitating mental health disorders, particularly post-traumatic stress, depression and anxiety.  

Mind Cure Health (OTCQB: MCURF; CSE: MCUR) is particularly well suited to this new research due to its outstanding Management team and world class Scientific Leaders and Advisors, Like Dr. Hartwell a PH.D. in experimental medicine and Dr. Dan Engle. Dr. Engle is world-renowned for his specializations in psychiatry and neurology. With a background in integrative psychiatry, neurocognitive restoration, peak performance medicine and psychedelic research, and is one of America though leaders on Psychedlic Medicine.  

Here are five reasons why investors are taking a closer look at new neuro-pharmaceutical stocks and companies such as Mind Cure (OTCQB: MCURF; CSE: MCUR).

Reason 1: Demand for New Mental Health Technologies is Off the Charts!

According to the National Institute of Mental Health, an estimated 47 million⁸ Americans (19.1%) suffer from some form of mental illness and at least 11 million⁹ from serious mental illness. The conditions range from depression, anxiety and post-traumatic stress to severe addiction, bipolar disorder and schizophrenia.  

What’s more, the situation appears to be getting worse – much worse.  

A new survey from the Centers for Disease Control (CDC) found that a staggering 41%¹⁰ of respondents are struggling with mental health issues stemming from the COVID-19 pandemic, resulting in skyrocketing rates of homelessness, drug addiction, violent crime and domestic abuse. 

Another study found a surge in the number of attempted suicides, emergency room hospitalizations, and police calls associated with mental illness.¹¹

Plus, the economic costs are staggering.  

In 2010, the global cost to treat mental health disorders was estimated at $2.5 trillion.¹²  

According to the World Economic Forum, between 2011 and 2030 mental health disorders will cost the global economy $16 trillion in lost output.¹³

As a result, the U.S. Food and Drug Administration (FDA) has recently given the go-ahead for new research into psychoactive compounds that could revolutionize mental health treatment – precisely the compounds that Mind Cure (OTCQB:MCURF; CSE:MCUR) is now bringing to market. 

And that leads to the second reason investors are intrigued...
 

Reason 2: The supply of mental health solutions is limited and getting smaller

There are few resources available for people with serious mental illness and their families – at least, few that ordinary people can afford.

Psychiatrists often do not accept insurance.  And they can charge between $300 and $600 per visit.

Treatment facilities for conditions such as addiction or bipolar disorder can cost upwards of $100,000.

In fact, the demand for mental health treatment is so high that in some parts of the United States patients must wait for up to a year before even seeing a specialist.¹⁴

Plus, the drugs currently offered for many conditions haven’t changed in nearly a century, such as lithium, and have debilitating side effects of their own.

Some drugs used to treat bipolar disorder, for example, such as anti-psychotics, are essentially heavy tranquilizers that leave patients feeling listless and sleepy. 

Common drugs used to treat depression and anxiety, such as selective serotonin reuptake inhibitors (SSRIs), also have potentially dangerous side effects.

In addition, Big Pharma has largely abandoned the development of new solutions.

According to the industry analyst Harry Tracy, who tracks developments in drug treatments for mental health problems, the number of drug research programs for new mental health drugs has declined by 70% in just the past 10 years.¹⁵

One reason:  while SSRIs have made the big drug companies literally billions of dollars in profits, the competition from generic replacements has resulted in a sharp decline of revenue.

In addition, the cost of developing new drugs is hugely expensive.  

As a result, many Big Pharma companies decided that it’s easier to develop new cancer or diabetes treatments than drugs for mental health.

This has resulted in a HUGE opportunity for companies such as Mind Cure (OTCQB: MCURF; CSE: MCUR), looking to research the therapeutic potential of substances already available and outside of patent protection, such as MDMA, Psilocybin and Esketamine. 

The FDA recently approved research on micro-doses of esketamine, a well-known anesthetic and tranquilizer, as a possible treatment for depression and anxiety.

In addition, the FDA has granted Breakthrough Therapy designations to two other once-controversial psychedelic compounds, MDMA (the active ingredient in the drug known as Ecstasy) and Psilocybin.

Both of these compounds show new promise as mental health treatments in small, controlled doses.  
In fact, there are currently more than 100 clinical trials underway investigating the pyschedelic medical potential of MDMA and Psilocybin.
And that leads to another reason investors are looking at mental health stocks...

Reason 3: Silicon Valley and the U.S. Military Are Pouring Millions into Mental Health Research

Some of the biggest names in Silicon Valley are helping to fund new mental health startups that are providing much of the basic science research behind Mind Cure (OTCQB: MCURF; CSE: MCUR).

One research group, the Multidisciplinary Association of Psychedelic Studies (MAPS), just raised $30 million in six months from 2,500 donors.  

Among the donors interested in supporting Phase 3 trials of MDMA to treat post-traumatic stress were some of the biggest names in Silicon Valley, including Peter Thiel, a co-founder of Paypal; Tim Ferris, bestselling author and tech entrepreneur; Bob Parsons, the founder of Go-Daddy; Steve Jurveston of Space X and Tesla; and George Sarlo, founder of Walden Venture Capital.

Another research group attracting millions in funding is the Center for Psychedelic and Consciousness Research at John Hopkins School of Medicine.  It received $17 million in funding from Silicon Valley entrepreneurs, including Ferris, Matt Mullenweb, co-founder of WordPress; Balke Mycoskie of the TOMS shoe brand; and investor Craig Nerenberg.  

The Center’s research has demonstrated potential therapeutic benefits from micro-doses of psilocybin for patients suffering from addiction as well as from depression and anxiety from life threatening diseases, such as cancer. 

A third source of major funding for research is the U.S. military. 

In June, the U.S. Department of Defense’s – Defense Advanced Research Projects Agency (DARPA) announced it was investing $27 million investment in a new research initiative to develop a new class of psychedelics-inspired drugs at the University of North Carolina (UNC) School of Medicine.  

The research is looking at new ways to use esketamine and potentially psilocybin as fast-acting treatments for depression and anxiety.  In 2019, the FDA approved the first new drug for depression since Prozac in 1988, a nasal spray from Johnson & Johnson called Sprovata made from Esketamine.¹⁶

Researchers also believe these compound in small amounts could provide rapid relief for post-traumatic stress and without any mind-altering affects.¹⁷

The involvement of the U.S. military in funding research into next-generation mental health therapies could provide a huge boost to small companies such as Mind Cure (OTCQB: MCURF; CSE: MCUR).  
 

Reason 4: Companies Researching New Mental Health Treatments Are Mostly Based in Regulatory-Friendly Canada

Another reason many investors are interested in mental health stocks is because they are often based in Canada, not the U.S.  

Canada is one of the best places for investing in next-generation mental health treatments.  

The country has state-of-the-art research facilities and scientific talent yet faces far fewer of the regulatory and political obstacles that often exist in the U.S. when it comes to developing new drugs.

It is often far easier and faster to gain approval for clinical trials for new treatments in Canada – something seen with the CBD and medical cannabis industry. In contrast, drug research in the U.S. is often controversial, expensive and risky.

For example, the Canadian research organization Therapsil was approved for psilocybin research therapy, the first legal medical exemptions for psilocybin in Canada since 1970’s.

An example that investing in Canadian mental health companies is often a safe bet from a regulatory standpoint – similar to investing in Canadian medical cannabis companies in the earliest stages of the cannabis boom.  

In the U.S., it sometimes happens that a company pours hundreds of millions of dollars into developing a new drug and investors flock to the company, only to be stymied by last-minute regulatory or political obstacles.  

And that leads to another important consideration:

Reason 5: A Potential Blockbuster Opportunity for Investors

Investors who recognize a new industry and invest in the earliest stages often see the biggest profits.  

This was true of such industries as online shopping (Amazon), smart phones (Apple) and streaming video (Netflix).  

Early investors who bet on small Canadian medical cannabis stocks often made life-changing gains.

Now, investors are betting that the same thing could be happening with mental health stocks such as Mind Cure (OTCQB: MCURF; CSE:MCUR).

One reason:  the sheer size of the market for new mental health treatments!

The size of the legal cannabis market is around $19 billion annually.  

Yet according to a report by investment bank Canaccord Genuity, the estimated size of the market for new mental health treatments is $100 billion¹⁸ -- or five times larger.

What’s more, at the moment there are only a tiny handful of publicly traded companies developing these products, often with share prices below $1.

If the use of psychoactive compounds continues to grow in popularity as a realistic treatment for mental health disorders, the shares of these stocks could see significant increases in value.  

This is what happened with early investments in Canadian medical marijuana stocks.  Cronos Group (NASDAQ: CRON) began trading around $1 a share in 2014 and eventually hit a high in 2019 of $21 – a 20-time return on investment.    

Canopy Growth (NYSE: CGC) also saw similar gains.  It began trading about $1.21 a share in 2015 and eventually hit a high of $50 a share in April 2019 – a total return of 4,032% or 40 times investment.

No guarantees, but this is why so many investors are taking hard looks at companies such as Mind Cure (OTCQB: MCURF; CSE: MCUR).  

 

Next steps for you to take...

Given the potential size of this opportunity, it may be a good idea to begin your research and due diligence sooner rather than later.

Below are a number of links to websites that provide more detail. Most important (and useful) will be to go straight to the Mind Cure (OTCQB: MCURF; CSE: MCUR) corporate website.  

It’s full of valuable information about the company, the use of psychoactive compounds in mental health treatment, and why the burgeoning mental health industry could lead to a boom similar to the medical cannabis boom of 2014-19

While on www.mindcure.com, be sure to register your name and email address with the company on its contact page! All future announcements and progress reports issued through the company’s email database can then be delivered immediately to your inbox. That should keep you ahead of the crowds and in position to move quickly on opportunity.